What Абиратерон НВ treats: Main Uses and Benefits

This medication is generally used to treat advanced prostate cancer that has spread to other parts of the body (metastatic status). It is applicable for patients with castration-resistant prostate cancer (CRPC), or those with certain high-risk castration-sensitive forms. In these contexts, the treatment may contribute to disease management and plays a role in supporting sustained disease management.

Абиратерон НВ helps with the management of biological signs that signal disease activity. It is commonly used when healthcare providers are aiming to address rising Prostate-Specific Antigen (PSA) levels and to assist in postponing radiographic progression (the spread or growth visible on scans). This management may assist with delaying the initiation of more intensive systemic treatments.

The medication is commonly used to help manage symptoms associated with advancing illness, which may include physical discomfort often linked to disease progression. By helping with disease management, the treatment may contribute to easing the overall symptom load. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Disease Progression and Discomfort
The medicine is relevant for easing symptoms that interfere with daily comfort and is applied in contexts involving heightened systemic burden in advanced prostate cancer.

Regulatory References

1. National Cancer Institute

Eligibility Map: Who Can and Cannot Use Абиратерон НВ — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for Абиратерон НВ (Abiraterone acetate), based strictly on government regulatory documents.

---

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult men are the approved population for the treatment of specific types of prostate cancer.
Populations for whom use is contraindicated	Women who are or may become pregnant and patients with baseline severe hepatic impairment (Child-Pugh Class C).
Age-related eligibility rules	Use is limited to adults; safety and efficacy are not established in the pediatric population.
Condition-specific eligibility rules	Use is contraindicated in severe hepatic impairment. Use in moderate hepatic impairment (Child-Pugh Class B) is restricted and requires cautious assessment.
Eligibility-related restrictions	Patients with a history of significant cardiovascular disease (e.g., severe heart failure) were excluded from pivotal clinical trials; safety in these specific groups is not established. Males with female partners of reproductive potential must use effective contraception.

---

Official regulatory documents define the eligible population as adult men with the treated condition and clearly establish contraindications for women who are or may be pregnant and for patients with severe liver impairment. The regulatory profile mandates that use must be cautiously assessed in patients with moderate liver impairment and in those with high-risk pre-existing cardiovascular conditions.

Interactions with other medicines and products

Regulatory documents outline specific interactions for Abiraterone acetate, primarily related to pharmacokinetic changes (drug concentration) and administration timing.

Interaction Type	Official Regulatory Statement
Timing Restriction (Food)	This medicine must be taken on an empty stomach due to a documented food effect. Co-administration with food, particularly a high-fat meal, significantly increases systemic exposure (AUC), which is officially restricted. Administration requires no food for at least two hours before and one hour after the dose.
Metabolic Inhibition	Abiraterone is documented to inhibit the drug-metabolizing enzymes CYP2D6 and CYP2C8. Co-administration with sensitive substrates of these enzymes, such as Repaglinide or Pioglitazone, may result in increased plasma concentrations of the co-administered medicine.
Contraindicated Combination	The combination of Abiraterone acetate (plus prednisone/prednisolone) with Radium Ra 223 Dichloride is officially not recommended or contraindicated due to documented increased risk of fractures and mortality observed in clinical trials.
Exposure Reduction	The use of strong CYP3A4 inducers (e.g., Rifampin, Phenytoin) is restricted because they are officially documented to decrease the systemic exposure of Abiraterone, potentially affecting its activity.
Pharmacodynamic Effect	Co-administration with the anti-androgen Spironolactone is restricted due to a documented pharmacodynamic interference that may increase serum Prostate-Specific Antigen (PSA) levels.
Population Constraint	Use is formally contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) because this condition results in significantly altered and increased systemic drug exposure.

These constraints define the medicine's interaction profile across various substance categories, with the most critical restriction being the mandatory fasting condition to maintain predictable drug concentration.

The mechanism of action for Абиратерон НВ (Abiraterone) is centered on its ability to significantly alter the body's processes for synthesizing steroid hormones.

Specific Inhibition of Hormone Production

The core mechanism involves acting as a selective inhibitor of the CYP17A1 enzyme, a crucial biological target found in the adrenal glands, testes, and elsewhere. By blocking this enzyme, the drug executes a highly specific molecular step that prevents the creation of male hormones (androgens) such as testosterone. This action initiates a cascade that leads to the systemic lowering of circulating androgens. This physiological state limits the availability of androgens required for cellular signaling.

Pathway Consequence: Mineralocorticoid Axis Modulation

The blockade of CYP17A1 non-selectively impacts the synthesis of cortisol, which disrupts the body’s hormonal feedback loop (HPA axis). This causes a compensatory surge of ACTH, shunting steroid precursors toward other available synthesis routes, resulting in the formation of mineralocorticoid-like steroids (e.g., deoxycorticosterone). This pathway diversion is an inherent mechanistic consequence that modulates the mineralocorticoid axis.

Mechanism Limitations

A known limitation of this action is the potential for metabolic interference, where the drug's metabolite, 5alpha-abiraterone, displays weak Androgen Receptor agonism. This secondary activity may partially interfere with the drug's primary anti-androgenic mechanism, challenging the overall suppression of androgen signaling.

How to Use Абиратерон НВ

Абиратерон НВ is administered via the oral route as a film-coated tablet. The standard regimen for adult use involves a daily dose of 1,000 mg of abiraterone acetate. This medicine is classified as a long-term treatment and is generally continued daily until criteria for discontinuation, such as disease progression, are met.

A key principle of its usage is the strict administration timing concerning food intake. The daily dose must be taken on an empty stomach, specifically avoiding any food consumption for at least two hours before and one hour after taking the tablets, to control the medicine’s absorption. The tablets should be swallowed whole using water and must not be crushed or chewed, as this alters the intended systemic delivery.

Usage Protocol and Adjustments

The overall treatment is structured as a combination therapy that involves the concurrent daily use of a low-dose corticosteroid, such as prednisone or prednisolone. If a dose is missed, the next scheduled daily dose should be taken, but a double dose should not be taken to compensate for the missed administration.

For certain specific patient populations, such as those with pre-existing moderate hepatic impairment (Child-Pugh Class B), the starting dose is reduced to 250 mg once daily. No adjustment is typically required for patients with renal impairment. This daily, continuous protocol, including specific dose adjustments and the empty stomach requirement, defines the standardized clinical administration pattern.

Research evidence / Overview of studies for Абиратерон НВ

Research examined the use of Abiraterone НВ in clinical studies exploring outcomes related to physical discomfort and systemic or functional imbalance. This evidence is generally derived from large-scale, randomized clinical trials (RCTs) that compared the drug combination against a placebo or standard treatment regimen.

Evidence for use in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Studies were conducted to examine Abiraterone НВ in conditions marked by functional limitations and involving periods of heightened symptoms in patients with progressive disease. The research explored the use of the drug in two main scenarios: patients who had previously received chemotherapy and those who were chemotherapy-naïve. The available findings describe patterns observed in these distinct populations. Research reports data related to outcomes that reflect short-term changes, such as Prostate-Specific Antigen (PSA) progression and physical discomfort. The research describes that measurements related to systemic or functional imbalance were taken during the study period, often comparing the group receiving the study drug to a group receiving a placebo.

Evidence for use in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Abiraterone НВ was evaluated in large-scale RCTs for newly diagnosed, metastatic, hormone-sensitive patients. Studies monitored outcomes including Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) when the drug was added to standard hormone therapy. The research describes that the comparison groups typically received standard hormone therapy alone. Studies monitored time to the first skeletal-related event as one of the measured outcomes. The collected data describes symptom patterns and how symptoms evolved in the observed populations.

Long-term studies and follow-up

Research has monitored the study populations over defined time intervals to assess long-term evidence. Follow-up periods in pivotal regulatory studies often extended to observation times of 30 months to 49 months or longer in final analyses. These studies explored whether the patterns observed in short-term research persisted over intermediate timeframes. While the collected data describes symptom patterns and long-term outcome measurements, long-term effects are not fully established beyond the observation period of the main trials.

Evidence in specific patient groups

Studies explored conditions where certain patient characteristics may influence results. Data for certain groups remain insufficient, particularly for those with severe cardiovascular comorbidities (such as advanced heart failure) or significant hepatic impairment (liver function issues). These groups were often excluded from the large regulatory RCTs. Research describes that measurements of drug concentrations in the body were taken and were associated with patient age in some studies. Data for the very elderly often remains limited.

What is still uncertain about Abiraterone Acetate

Research highlights what is known—and what is still uncertain. Evidence quality varies across studies, and certainty remains low for specific, small subgroups. A major limitation is that the design of some initial trials allowed patients to switch from the control arm to the active study drug arm, which can complicate the final interpretation of long-term overall survival endpoints. Furthermore, comparative evidence is lacking for many direct, head-to-head comparisons with other contemporary treatments. The study results reflect the specific conditions under which they were conducted.

Common questions about Абиратерон НВ (FAQ)

---

Q: Is Абиратерон НВ considered a chemotherapy drug?

No, this medicine is not classified as a traditional cytotoxic chemotherapy agent. Official regulatory sources list its pharmacological class as an Antineoplastic Agent and a Hormone Antagonist. It specifically works by inhibiting a key enzyme in the hormone production process.

---

Q: Is there a generic version of Абиратерон НВ available?

Regulatory agencies in various regions have approved generic versions containing the active substance abiraterone acetate. These generics are approved because they are determined to be bioequivalent, meaning they are absorbed by the body in a way comparable to the original medicine.

---

Q: What kind of monitoring tests are usually needed while on Абиратерон НВ?

According to official product information, patients typically undergo regular blood tests to monitor liver function (such as liver enzymes) and blood potassium levels. These checks are necessary because the medicine can potentially affect both the liver and the body's mineral balance. The required monitoring frequency is often detailed for the initial months of treatment.

---

Q: Are there any known food or drink restrictions while using Абиратерон НВ?

Official regulatory information indicates the medicine is administered on an empty stomach. The product labeling specifies restrictions on consuming food for a defined period both before and after administration. This protocol is in place because eating significantly increases the amount of medicine absorbed, which can disrupt the intended treatment effect.

---

Q: Is age a major factor in who can receive Абиратерон НВ?

Official regulatory documents approve the use of the drug only in the adult population. While studies have included analysis across different adult age groups, data on the very elderly may sometimes be limited. However, no special dose adjustment is required based solely on a patient's age.

---

Q: What are the research-backed benefits of Абиратерон НВ?

Research evidence from clinical trials reports that this treatment regimen was associated with a prolonged overall survival and improved radiographic progression-free survival in patients with the approved condition. These outcomes are measures used in trials to assess the effects of the medicine on the course of the illness.

---

Q: Is there a risk of bone thinning (osteoporosis) associated with Абиратерон НВ treatment?

Official documents note that fractures were observed in clinical trials. The risk of bone thinning (osteoporosis) and related fractures is a recognized concern that is often associated with the underlying condition and the required use of low-dose corticosteroids alongside the drug.

---

Q: Can Абиратерон НВ affect fertility in men?

Studies and official information indicate that, due to the drug's action on hormone pathways, it may affect male fertility. Official product labeling specifies that effective contraception is required for males with female partners of reproductive potential during treatment and for a defined period after the last dose.

---

Q: What are the symptoms of common side effects associated with Абиратерон НВ?

Regulatory documents list physical symptoms that patients should be aware of, particularly those related to changes in the body's mineral balance. These can include high blood pressure, fluid retention (e.g., swelling or weight gain), and signs of low blood potassium like muscle weakness, cramps, or an irregular heartbeat.

---

Q: Does Абиратерон НВ affect the ability to drive or operate machinery?

Regulatory information notes that side effects such as fatigue and dizziness have been reported. Due to the reporting of these effects, official information advises that caution should be exercised when driving or operating machinery.

---

Q: What happens when treatment with Абиратерон НВ is stopped?

The product label states that the decision to discontinue the medicine must be made by a healthcare provider. Abrupt cessation of the drug may be associated with a rebound in testosterone or, if the concurrent corticosteroid is also stopped, can lead to symptoms of adrenal insufficiency. A temporary decrease in PSA is also sometimes observed.

---

Q: Why is Абиратерон НВ used in combination with other drugs sometimes?

The medicine is administered in combination with a low-dose corticosteroid, such as prednisone, as required by the official usage protocol. This is done to mitigate side effects, particularly those related to high blood pressure and low blood potassium, which can occur due to the drug's mechanism of action.

---

Q: Does Абиратерон НВ have any known effects on cholesterol levels?

According to data published in official regulatory labels, high blood triglyceride levels (hypertriglyceridemia) were observed as a common laboratory abnormality in patients during clinical studies.

---

Q: Are allergic reactions to Абиратерон НВ possible?

Yes, official product information specifies that the presence of known hypersensitivity to the active substance or its excipients constitutes a contraindication for use. Hypersensitivity to components of the medicine has been reported.

---

Q: Does taking Абиратерон НВ affect sleep patterns?

Official regulatory documents list insomnia (difficulty falling or staying asleep) as an adverse reaction that was reported in patients during clinical trials.

The storage and disposal of Abiraterone Acetate (Абиратерон НВ) are strictly governed by regulatory requirements to ensure product quality and safety.

Storage Conditions

Abiraterone tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with limited temperature excursions permitted. To protect the medicine from light and moisture and maintain stability, it must be kept in its original container and the container must remain tightly closed in a dry, cool, and well-ventilated area.

Safety and Disposal

For child protection, the medication must be stored locked up and securely out of the reach of children. Regarding disposal, the product is classified as an environmental hazard. It must not be released into the environment, including flushing it down sinks or toilets, and unused portions must be disposed of strictly according to local regulations for medicinal waste.